Three semaglutide products, three different jobs
Wegovy, Ozempic, and Rybelsus all contain semaglutide. Treating them as interchangeable is the most common and most costly mistake patients make.
Wegovy, Ozempic, and Rybelsus are all Novo Nordisk semaglutide products, but they differ by approved indication, dose, and form. Wegovy (injectable, up to 2.4 mg weekly) is approved for chronic weight management and cardiovascular risk reduction. Ozempic (injectable, up to 2 mg weekly) is approved for type 2 diabetes and CV risk reduction. Rybelsus (oral tablet, up to 14 mg daily) is approved for type 2 diabetes. Insurance coverage and cash price differ sharply among them.
- One molecule, three approvals: Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying.
- Wegovy: Wegovy is injectable semaglutide titrated to 2.4 mg weekly, approved for chronic weight management in adults and adolescents with obesity, and — based.
- Ozempic: Ozempic is injectable semaglutide titrated to 1 or 2 mg weekly, approved for type 2 diabetes and, like Wegovy, for cardiovascular risk reduction in ad.
- Rybelsus: Rybelsus is oral semaglutide, a daily tablet approved for type 2 diabetes at doses up to 14 mg.
- How cost and coverage differ: Because indication drives coverage, the three products can cost wildly different amounts for the same person.
One molecule, three approvals
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. Novo Nordisk developed three products around it, and the FDA approved each for specific uses based on specific trials. The molecule being identical does not make the products interchangeable, because approval, dose, and form differ — and those differences drive coverage and cost.
This is why a prescriber writes for one specifically, and why insurance treats them differently: a plan may cover Ozempic for diabetes while excluding Wegovy for weight loss, even though both are semaglutide. The indication on the prescription, not the molecule, determines what your plan pays.
| Wegovy | Ozempic | Rybelsus | |
|---|---|---|---|
| Form | Injection (weekly) | Injection (weekly) | Tablet (daily) |
| Approved for | Weight mgmt + CV risk | Type 2 diabetes + CV risk | Type 2 diabetes |
| Max dose | 2.4 mg | 2 mg | 14 mg |
| Key trials | STEP, SELECT | SUSTAIN, SELECT-adjacent | PIONEER |
| Typical coverage | Weight-loss exclusions common | Diabetes criteria | Diabetes criteria |
Wegovy: weight management and heart risk
Wegovy is injectable semaglutide titrated to 2.4 mg weekly, approved for chronic weight management in adults and adolescents with obesity, and — based on the SELECT trial — for reducing cardiovascular events in adults with established cardiovascular disease and obesity or overweight. In STEP-1, participants averaged about 14.9 percent weight loss.
Wegovy is the semaglutide product to think of first for weight loss. Self-pay pricing runs in the several-hundred-dollars-per-month range through NovoCare and retail, and the new Wegovy pill (oral semaglutide 25 mg) extends the brand into an oral option for weight management — a different product again, covered in our Wegovy pill guide.
Ozempic: diabetes first
Ozempic is injectable semaglutide titrated to 1 or 2 mg weekly, approved for type 2 diabetes and, like Wegovy, for cardiovascular risk reduction in adults with type 2 diabetes and established CV disease. Its enormous fame comes largely from off-label weight-loss use, but its label is diabetes.
For a patient with type 2 diabetes, Ozempic is often the covered, on-label choice, and plans routinely cover it under diabetes criteria. For weight loss without diabetes, prescribing Ozempic is off-label, and coverage is unreliable — which is exactly the situation that pushed many patients toward Wegovy or compounded semaglutide in the first place.
Rybelsus: the oral diabetes tablet
Rybelsus is oral semaglutide, a daily tablet approved for type 2 diabetes at doses up to 14 mg. It relies on the SNAC absorption enhancer and a strict empty-stomach protocol because oral peptide bioavailability is low. It is the product most often confused with, and misused to justify, compounded sublingual products.
Two clarifications matter. Rybelsus is approved for diabetes, not weight management — the new 25 mg Wegovy pill is the weight-management oral. And Rybelsus's evidence does not transfer to compounded sublingual ODT products, which use a different route and no SNAC, as our ODT evidence guide details.
How cost and coverage differ
Because indication drives coverage, the three products can cost wildly different amounts for the same person. A diabetic patient may pay a modest copay for Ozempic or Rybelsus while the same plan excludes Wegovy for weight loss. A cash-pay weight-loss patient faces several hundred dollars a month for Wegovy, versus the compounded semaglutide floor near $100–$200 — with the compounding-legality caveats covered elsewhere on this site.
The 2027 Medicare negotiated price adds another layer: semaglutide products (Ozempic, Wegovy, Rybelsus were negotiated together) land at a lower maximum fair price for eligible beneficiaries starting January 2027. For most people, though, the near-term cost is set by which product, which indication, and which plan.
How to choose (with your prescriber)
The decision is indication-led. Type 2 diabetes: Ozempic or Rybelsus are the on-label, usually-covered choices. Weight management by injection: Wegovy. Weight management, needle-averse: the Wegovy pill (approved) rather than an unproven compounded sublingual product. Established cardiovascular disease: Wegovy or Ozempic carry the CV indication that can unlock coverage.
Whatever the target, the product on your prescription determines coverage and cost far more than the molecule does. If a program blurs the three — implying compounded semaglutide is “the same as Ozempic” — that is a marketing simplification to see through, not a clinical fact to rely on.
It also helps to understand why Novo Nordisk built three products rather than one. Different indications require different trial programs, different doses, and different regulatory submissions, and payers negotiate each separately. A single 'semaglutide' product could not carry a diabetes label, a weight-management label, and a cardiovascular label at three different dose ceilings, because the evidence supporting each use was generated in distinct trials. The three-product structure is a direct reflection of how drug approval and insurance coverage actually work, which is exactly why treating the products as interchangeable breaks down the moment a claim is filed.
Frequently asked questions
Are Wegovy, Ozempic, and Rybelsus interchangeable?
No. They share the semaglutide molecule but differ in approved indication, dose, and form. Coverage and cost follow the indication on your prescription, not the molecule, so they are not swappable without a prescriber's decision.
Which one is for weight loss?
Wegovy (injection) and the newer Wegovy pill (oral 25 mg) are approved for weight management. Ozempic and Rybelsus are approved for type 2 diabetes; weight-loss use of those is off-label.
Is compounded semaglutide 'the same as' any of these?
No. Compounded semaglutide is not FDA-approved and is not any of these brand products. It should be evaluated on its own evidence and legality, not by borrowing the brands' approvals.
Sources
- FDA — Drugs@FDA (Wegovy, Ozempic, Rybelsus labels)
- STEP-1 (NEJM 2021)
- SELECT cardiovascular outcomes (NEJM 2023)
- PIONEER program (oral semaglutide, PubMed)
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Checking the figures in semaglutide
The semaglutide figures on this page span $119 to $299 a month across 12 programmes. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.